JEMPERLI offers women meaningful results

JEMPERLI, an immunotherapy, was proven effective in a clinical trial of women with recurrent or advanced mismatch repair deficient, or dMMR, endometrial cancer

JEMPERLI was studied in 71 women with recurrent or advanced dMMR endometrial cancer that had progressed on or following prior chemotherapy containing platinum.

What is the importance of dMMR in endometrial cancer?

JEMPERLI helped women’s tumors shrink or completely disappear

Infographic with data showing how JEMPERLI (dostarlimab-gxly) helped women's tumors shrink or completely disappear. 42.3% of women had tumors completely disappear or partially shrink. Tumors completely disappeared in 12.7% of women. Tumors partially shrank in 29.6% of women.

*This does not always mean that the cancer has been cured.

Many women in the study had a continued response with JEMPERLI

Image: Portrait of woman 2

93.3% of women who responded to therapy had an ongoing response for 6 months or longer

In women who achieved a response, the duration of their responses ranged from 2.6 to 22.4+ months with the median not reached. Follow-up for half of these women was at least 14.1 months.

Still responding at last follow-up.

Icon: Gears

How may JEMPERLI fight cancer?

See How JEMPERLI Works

Icon: JEMPERLI (dostarlimab-gxly) Side Effects

What are the side effects of JEMPERLI?

Learn More About Treatment